Real-life cost-effectiveness of benralizumab in patients with severe asthma.

ABSTRACT:

Background

Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after incorporating benralizumab into the standard treatment of refractory eosinophilic asthma.

Methods

This was a cross-sectional multicentre study of consecutive patients with refractory eosinophilic asthma who received treatment with benralizumab during at least 12 months. Patient follow-up was performed in specialised severe asthma units. The main effectiveness parameters measured were: the avoidance of one asthma exacerbation, a 3-point increase in the asthma control test (ACT) score, and the difference in utility scores (health-r

SUBMITTER: Padilla-Galo A 

PROVIDER: S-EPMC8155800 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature